by Gian Luigi Lenzi
The first paper that I would like to point out to Neuropenews readers has been published in a very “peripheral” Journal, such as Missouri Medicine, at least in respect to European Neurology. However, the paper “Beta blocker eye drops for treatment of acute migraine”, by Migliazzo CV, and JC Hagan, Missouri Medicine, 111, 2014, 283-288 has been highly “tagged” by neurologists. Seven cases of acute migraine patients, successfully treated with beta blocker eye drops are reported.
The second paper that I would like to signal to our readers is one of the many papers recently presented/published on long term positive effects of MS therapies. This particular report has been presented by Ludwig Kappos, a leader in MS field, at the annual (2014) Meeting of the ANA, and it refers to the BENEFIT 11 trial; that is, the 11-year follow-up of the original BENEFIT (Betaferon/Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) trial. The AA state that “relapse-related clinical outcomes still favour patients who had early treatment with interferon-beta-1b relative to those in the delayed interferon beta-1b treatment arm”. Similar positive results (on brain atrophy, cognitive impairment, disability, etc.) with different therapeutical approaches (and sponsors) in CIS or initial MS patients have been recently presented by other MS Leaders. To me, the final message looks as “treat as early as possible, regardless of clinical, MRI, and/or other presentations”.
